Subscribe to this blog

Follow by Email

Search This Blog

Pages

First Baby Born in Scotland Using New Ground-Breaking IVF Technology

GLASGOW, Scotland, June 14, 2013

Baby Eva named after the test that gave her life

by F Guzzardi

The Glasgow Centre for Reproductive Medicine (GCRM) one of the UK's most innovative IVF clinics, announces the birth of the first baby to be born in Scotland using a ground-breaking new approach to IVF, The 'Early Embryo Viability Assessment' (Eeva) test, that improves embryo selection.

Scotland is welcoming Baby Eva today, the world's first baby to be born and named by her parents after the new Eeva test. Eva was born on 11 June following Susan Walker-Dempster and David Dempster
hardship of trying to build a family together. Susan and David chose to
have the Eeva test at the GCRM to increase their chances of IVF
success. The new mother, Susan said "we wanted every chance to be
successful, so we chose Eeva"

The Eeva test uses unique predictive software in combination with a
time-lapse analysis technique to automatically analyse embryo
development against scientifically and clinically validated
cell-division parameters. The test aids embryologists in selecting the
most viable embryos for transfer, potentially increasing the chances of a
successful IVF cycle.

Scientist Professor Richard Fleming at
GCRM said: "We are very proud to be among the first clinics in the
world to announce this news as it demonstrates how successful this new
technology can be in enabling couples to have a higher chance of
conceiving a baby with IVF. GCRM has always strived to be one of the
leading IVF Centres in Europe, offering
couples the latest innovations with the best possible outcomes. The
Eeva test is the practical end point of good quality research and is the
start of a new chapter in the evolution of IVF."

"We are delighted to hear the news of this successful birth and wish the family the very best. " said Lissa Goldenstein,
president and CEO of Auxogyn Inc "The Eeva test has been developed to
give IVF clinicians objective information about the embryo and provide
insight into its growth potential. With more couples choosing to use
Eeva, we are looking forward to many more births like Baby Eva today."

About IVF

Infertility affects one out of every 7 couples in the United Kingdom.
The demand for assisted reproduction tools and procedures is growing
worldwide . This growth is occurring despite the significant cost per
IVF cycle and the low success rate, with approximately one-third of
cycles resulting in a live birth. This necessitates the transfer of
multiple embryos and/or conducting multiple cycles, leading to greater
physical, emotional, practical and financial costs, before determining
if pregnancy can be achieved.

About GCRM

GCRM is a member of the 'Academic
Reproductive Partnership' (ARP). ARP was formed by the merger of a
number of the UK's leading fertility clinics. The partnership is
currently the largest single provider of NHS and private IVF services in
the UK.

GCRM provides patients with access to the very latest fertility
treatment techniques. Patients also benefit from the sharing of best
practice and scientific resources by teams across theUKwho are at the pinnacle of the assisted reproduction sector. Please visit http://www.gcrm.co.ukfor more information.

About the Early Embryo Viability Assessment (Eeva) Test

The Eeva test provides IVF clinicians with
predictive information about the embryo's development potential to help
improve embryo selection. Eeva's proprietary software automatically
analyzes embryo development against scientifically and clinically
validated cell-division parameters conceived by researchers at Stanford University
in the US. With results from the Eeva test, IVF teams now have
predictive and objective information to combine morphological assessment
to help improve the embryo selection decision. The Eeva Test was
validated in a prospective, multi-centre, 54-patient clinical trial with
758 embryos. Embryologists using Eeva were significantly able to
improve their ability to identify non-viable embryos relative to
traditional methods alone. Additionally, Eeva was able to increase the
consistency of embryo assessment across embryologists. Results of this
study were presented in July 2012 at the
European Society of Human Reproduction and Embryology (ESHRE) Annual
Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.

Eeva is currently CE Marked and available for use in the EU and is pending FDA clearance in theUnited States. For a full list of clinics offering the Eeva test please visit http://www.eevaivf.comor follow us on Twitter @EevaIVF.